Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v5-FR | Version v5-FR | |
---|---|---|
Language | French | French |
Date Updated | 2022-11-02 | 2022-11-02 |
Drug Identification Number | 02430827 | 02430827 |
Brand name | LINEZOLID INJECTION | LINEZOLID INJECTION |
Common or Proper name | LINEZOLID INJECTION | LINEZOLID INJECTION |
Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
Ingredients | LINEZOLID | LINEZOLID |
Strength(s) | 2MG | 2MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 300 mL | 300 mL |
ATC code | J01XX | J01XX |
ATC description | OTHER ANTIBACTERIALS | OTHER ANTIBACTERIALS |
Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
Anticipated start date | 2022-07-01 | 2022-07-01 |
Actual start date | 2022-07-01 | 2022-07-01 |
Estimated end date | Unknown | Unknown |
Actual end date | 2022-11-01 | 2022-11-01 |
Shortage status | Resolved | Resolved |
Tier 3 Status | No | No |
Company comments | our Linezolid Injection 2 mg/mL freeflex® Bag 300 mL will be available at all distribution centres by July 1, 2022. Once available, this product will be placed on allocation. Contract customers will be allocated 100% of historical monthly demand | our Linezolid Injection 2 mg/mL freeflex® Bag 300 mL will be available at all distribution centres by July 1, 2022. Once available, this product will be placed on allocation. Contract customers will be allocated 100% of historical monthly demand |
Health Canada comments |